Sort   by:  
 Page size 
UnknownPhase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Not available
S-EPMC5562171 | biostudies-literature
UnknownImpact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
Not available
S-EPMC9204731 | biostudies-literature
UnknownDurvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Not available
S-EPMC10870117 | biostudies-literature
UnknownDurvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Not available
S-EPMC9161394 | biostudies-literature
Sort   by:  
 Page size